Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Julie‐Anne Scott"'
Autor:
Svenja Harvey, Mark Stares, Julie‐Anne Scott, Tharun Joseph Vattam Thottiyil, Alicia‐Marie Conway, Rachel Haigh, Jackie Brown, Gillian Knowles, Sonali Dasgupta, Kai‐Keen Shiu, Claire Mitchell, Colin Barrie, Natalie Cook, Sally Clive
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Background Biomarkers of systemic inflammation have been shown to predict outcomes in patients with cancer of unknown primary (CUP). We sought to validate these findings in patients with confirmed CUP (cCUP) and explore their role alongside
Externí odkaz:
https://doaj.org/article/c5055b489f1a43e8828eba5e72f48749
Publikováno v:
Journal of Clinical Oncology. 39:5028-5028
5028 Background: Salvage therapy for relapsed or refractory germ cell tumours (GCTs) after first-line treatment (1LT) failure remain controversial. The ongoing TIGER trial aims to compare conventional-dose chemotherapy (CDCT) using TIP with high-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aac6abcc54e8e9cba1c178942f75aba
https://doi.org/10.1200/jco.2021.39.15_suppl.5028
https://doi.org/10.1200/jco.2021.39.15_suppl.5028
Autor:
Natalie Cook, Donna M. Graham, Julie-Anne Scott, Sreeja Aruketty, Matthew G Krebs, Hitesh Mistry, Matt Church, Aidi Adamson-Raieste, Louise Carter, Fiona C Thistlethwaite, Rozana Abdul Rahman, Neethu Billy Graham Mariam
Publikováno v:
Journal of Clinical Oncology. 39:3133-3133
3133 Background: The primary objective of EPCCT (phase I and non-randomised phase II trials) is to determine the safety and tolerability of new therapeutic agents. Response rates (RR) in these trials have typically been reported at around 10-15%. Inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a00d7f83b9864d50dc7ad2a8012c26a3
https://doi.org/10.1200/jco.2021.39.15_suppl.3133
https://doi.org/10.1200/jco.2021.39.15_suppl.3133